参麦注射液联合AG化疗方案对晚期不可切除胰腺癌患者肿瘤标志物及免疫功能的影响  

Effects of Shenmai Injection Combined with AG Chemotherapy Regimen on Tumor Markers and Immune Function in Patients with Advanced Unresectable Pancreatic Cancer

作　　者：田宁 张山燕 周远[1] 王娟 TIAN Ning;ZHANG Shanyan;ZHOU Yuan;WANG Juan(Department of Chemotherapy,Tai’an Tumour Prevention and Treatment Hospital,Tai’an 271000,China;不详)

机构地区：[1]泰安市肿瘤防治院化疗科,山东泰安271000

出　　处：《中国医学创新》2025年第12期17-20,共4页Medical Innovation of China

摘　　要：目的:探究参麦注射液与AG化疗方案联合应用对晚期不可切除胰腺癌患者肿瘤标志物及免疫功能的影响。方法:回顾性分析2021年1月—2023年6月泰安市肿瘤防治院收治的80例晚期不可切除胰腺癌患者的临床资料,根据治疗方案不同分为观察组与对照组,各40例。对照组给予AG化疗方案治疗,观察组在对照组基础上联合参麦注射液治疗。对比两组肿瘤标志物、免疫功能和临床疗效。结果:治疗后,两组癌胚抗原(CEA)、糖类抗原19-9(CA19-9)水平均下降,观察组均低于对照组(P<0.05);治疗后,两组CD3^(+)、CD4^(+)水平均升高,观察组均高于对照组,CD8^(+)水平均下降,观察组低于对照组(P<0.05);两组客观缓解率(ORR)、疾病控制率(DCR)、死亡率比较,差异均无统计学意义(P>0.05)。结论:参麦注射液联合AG化疗方案应用于晚期不可切除胰腺癌患者可降低肿瘤标志物水平,提高患者免疫功能。Objective:To explore the effects of Shenmai Injection combined with AG chemotherapy regimen on tumor markers and immune function in patients with advanced unresectable pancreatic cancer.Method:The clinical data of 80 patients with advanced unresectable pancreatic cancer admitted to Tai’an Tumour Prevention and Treatment Hospital from January 2021 to June 2023 were retrospectively analyzed,and they were divided into observation group and control group according to different treatment regimens,with 40 cases in each group.The control group was treated with AG chemotherapy regimen,and the observation group was treated with Shenmai Injection on the basis of control group.Tumor markers,immune function and clinical efficacy were compared between the two groups.Result:After treatment,the levels of carcinoembryonic antigen(CEA)and carbohydrate antigen 19-9(CA19-9)in both groups were decreased,and those in the observation group were lower than those in the control group(P<0.05).After treatment,the levels of CD3^(+)and CD4^(+)in both groups were increased,and those in the observation group were higher than those in the control group,the levels of CD8^(+)in both groups were decreased,and that in the observation group was lower than that in the control group(P<0.05).There were no significant differences in objective response rate(ORR),disease control rate(DCR)and mortality between the two groups(P>0.05).Conclusion:Shenmai Injection combined with AG chemotherapy regimen in patients with advanced unresectable pancreatic cancer can reduce the levels of tumor markers,improve the immune function of patients.

关 键 词：参麦注射液 AG化疗方案 胰腺癌 肿瘤标志物 免疫功能 

分 类 号：R735.9[医药卫生—肿瘤]